Arginine Supplement Reduces Alzheimer's Damage in Animal Models

A recent study suggests that the amino acid arginine may reduce damage associated with Alzheimer's disease. Researchers found that arginine reduced the buildup of toxic amyloid beta (Aβ) proteins in animal models. The study, published in *Neurochemistry International*, indicates that this common, inexpensive compound could offer a new approach to Alzheimer's treatment.

Scientists from Kindai University and partner institutions conducted the research. They observed that arginine, an amino acid already considered safe, could decrease harmful protein deposits. Oral administration of arginine also improved behavior and reduced brain inflammation in the animal models.

In laboratory tests, arginine prevented the formation of Aβ42 aggregates, which are particularly toxic. The effect was more pronounced with higher concentrations of arginine. The team then tested oral arginine in two established Alzheimer's models: a *Drosophila* (fruit fly) model and an *App NL-G-F* knock-in mouse model.

In both animal models, arginine treatment lowered Aβ accumulation and reduced its harmful effects. In the mouse model, arginine decreased amyloid plaque levels and insoluble Aβ42 in the brain. Treated mice also performed better on behavioral tests. The researchers also noted that arginine reduced the activity of genes linked to pro-inflammatory cytokines, which contribute to neuroinflammation in Alzheimer's disease.